CGRP mAb Subcutaneous denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Cites "Not FDA-Approved" for Subcutaneous CGRP Monoclonal Antibodies — and Why You Can Appeal

A "not FDA-approved" denial for a subcutaneous CGRP monoclonal antibody is one of the most important denials to challenge promptly, because several agents in this class do hold full FDA approval for migraine prevention. When this denial is issued, one of three things has likely occurred: (1) there is an administrative error in the prior authorization submission, such as a mismatched diagnosis code or the wrong drug name; (2) the specific use being requested is technically off-label (for example, a population or indication not listed in the approved labeling); or (3) Aetna's system has not yet registered a recent approval.

Identifying which scenario applies is the first task of the appeal.

## Federal Appeal Framework

Aetna is required under ACA Section 2719 to offer external review of adverse benefit determinations, including denials based on FDA status. ERISA Section 503 applies to employer-sponsored plans. File your internal appeal within approximately 180 days of the denial. If the internal appeal is upheld, you have approximately four months to request independent external review, where a reviewer with no financial relationship to Aetna will evaluate the denial. Expedited review is available for urgent clinical situations.

## Concrete Appeal Steps

1. Confirm from the denial letter the exact basis Aetna cited — did it say the drug is not approved at all, or that the specific use (indication, age group, or route) is not approved? 2. Obtain the current FDA-approved prescribing label for the specific agent from the FDA's official DailyMed database (dailymed.nlm.nih.gov) or the manufacturer's prescribing information. 3. Compare your prescriber's submitted indication against the approved labeling. If the use is on-label, the denial is likely an error and your appeal letter should state that directly, attaching the relevant label page. 4. If the use is off-label, your appeal should pivot to demonstrating medical necessity supported by the applicable professional guideline — Aetna must consider medically accepted indications, not only FDA labeling, under most plan terms.

## Documentation to Gather

• FDA prescribing label: printed or downloaded from DailyMed, with the approved indication highlighted — this is your primary evidence if the denial is an error
• Prior authorization submission records: confirming what diagnosis code and indication were submitted, to identify any administrative mismatch
• Prescriber medical-necessity letter: if the use is off-label, explaining why it is supported by the standard of care and referencing the applicable guideline organization
• Applicable guideline citation: reference to the American Headache Society or American Academy of Neurology position on the relevant use

## Criteria-Mapping Structure

In your appeal letter, address the FDA-approval question directly and factually: state the drug name, its FDA approval date, and the approved indication, citing the label. Then address Aetna's stated basis for the denial point by point. If the denial was in error, say so plainly and ask for immediate reversal. If the use is off-label, map the clinical-necessity argument to Aetna's off-label coverage criteria as published in its clinical policy.